NOVEL THERAPIES FOR ADVANCED UROLOGIC CANCERS: Edited by Shahrokh F. ShariatFibroblast growth factor receptors across urothelial carcinoma landscapeErtl, Iris E.a; Shariat, Shahrokh F.a,b,c,d,e,h; Mostafaei, Hadia,f; Ilijazi, Dafinaa; Loriot, YohanngAuthor Information aDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria bDepartment of Urology, Weill Cornell Medical College, New York, USA cDepartment of Urology, University of Texas Southwestern, Dallas, Texas, USA dDepartment of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic eInstitute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia fResearch Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran gDepartment of Cancer Medicine, Gustave Roussy Institute, INSERM 981, Cancer Campus, Grand Paris, University of Paris-Saclay, Villejuif, France hDepartment of Urology, University of Jordan, Amman, Jordan Correspondence to Shahrokh F. Shariat, MD, Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Tel: +43 1 40400 26150; e-mail: email@example.com Current Opinion in Urology: July 2020 - Volume 30 - Issue 4 - p 557-565 doi: 10.1097/MOU.0000000000000782 Buy Metrics Abstract Purpose of review Fibroblast growth factor receptor (FGFR) signalling, especially induced by FGFR3, is a crucial factor in the pathogenesis of urothelial carcinoma and was therefore extensively studied over the last decades. In this review, we summarize the most relevant findings of the past two years. Recent findings Recent studies support the concept that FGFR3 mediates a pathway of urothelial carcinogenesis associated with low malignant potential. FGFR3 may represent a highly accurate biomarker for diagnosis and prediction of recurrence, progression or therapy response. The pan FGFR-inhibitor erdafitinib was recently approved for urothelial carcinoma, whereas several other FGFR-targeted drugs are currently undergoing clinical trials. Summary Numerous recent studies focus on the role of FGFR3 in different urothelial carcinoma subtypes and its potential clinical application as noninvasive biomarker, as well as therapeutic target. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.